Previous 10 | Next 10 |
SAN DIEGO , July 16, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the a...
Gainers: Immunic (NASDAQ: IMUX ) +48% . Soliton (NASDAQ: SOLY ) +17% . Biomerica (NASDAQ: BMRA ) +14% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +13% . Cemtrex (NASDAQ: CETX ) +12% . Verastem (NASDAQ: VSTM ) +11% . Cigna Corporation (NYSE: CI ) +11% . Mastech Digital (NYS...
Immunic (NASDAQ: IMUX ) +17% . More news on: Immunic, Inc., Foresight Autonomous Holdings Ltd., Jaguar Health, Inc., Stocks on the move, Read more ...
Spectrum Pharmaceuticals (NASDAQ: SPPI ) initiated with Buy rating and $18 (114% upside) price target at B. Riley FBR. More news on: Spectrum Pharmaceuticals, Inc., Immunic, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red last week, dipping from 3,429.71 points on Monday’s (June 24) open to 3,410.20 points as of 12:14 p.m EDT on Friday (June 28). On Thursday (June 27), Dova Pharmaceuticals (NASDAQ: DOVA ) announced that it received an ...
Gainers: Pyxus International (NYSE: PYX ) +28% . Allergan (NYSE: AGN ) +26% . ENDRA Life Sciences (NASDAQ: NDRA ) +23% . Pier 1 Imports (NYSE: PIR ) +18% . Rafael Holdings (NYSEMKT: RFL ) +16% . Riot Blockchain (NASDAQ: RIOT ) +15% . Vislink Technologies (NASDAQ: VISL ) +15% ....
Acer Therapeutics (NASDAQ: ACER ) -79% after FDA rejects Edsivo application for rare connective tissue disorder. More news on: Acer Therapeutics Inc., Cemtrex, Inc., Aldeyra Therapeutics, Inc., Stocks on the move, Read more ...
SAN DIEGO , June 24, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella...
SAN DIEGO , June 21, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that ...
SAN DIEGO , June 4, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof , Ph.D., ...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
--News Direct-- Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology...
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, ...
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation Immunic Announces Publication of Extended Data From Phase 2 ...